Khaled Shahrour, Timothy D. Averch

Canadian Journal of Urology, Vol.18, No.1, pp. 5547-5547, 2011

Abstract This article has no abstract. More >

Abdulkader Alobaidy, Abdulla Al-Naimi, Khalid Assadiq, Haidar Alkhafaji, Abdulla Al-Ansari, Ahmed A. Shokeir

Canadian Journal of Urology, Vol.18, No.1, pp. 5542-5547, 2011

Abstract Objective: To identify the risk factors of unfavorable results of percutaneous nephrolithotomy (PCNL).
Patients and methods: A total of 602 patients were subjected to 616 PCNL procedures. Patients were divided into two groups according to the results of treatment. Group 1 with favorable results includes patients who became stone free after a single PCNL procedure without major complications. Group 2 with unfavorable results includes three subgroups: a) Patients who developed major complications, b) Those who required second major intervention to complete stone removal, and c) Patients with residual stones > 4 mm at 3 month. Risk factors… More >

Kevin R. Loughlin

Canadian Journal of Urology, Vol.18, No.1, pp. 5541-5541, 2011

Abstract This article has no abstract. More >

John B. Calhoun, Todd D. Merchen, James A. Brown

Canadian Journal of Urology, Vol.18, No.1, pp. 5537-5541, 2011

Abstract Introduction: Surgical volume correlates with improved outcomes for some complex urologic procedures. We reviewed the outcomes of a lower volume practice (1-2 cases per year) experience with radical nephrectomy with infra/retrohepatic vena caval thrombectomy (RNCT).
Methods: We retrospectively reviewed 10 patients who underwent RNCT performed by a single surgeon at a single state institution over 7 years (2002-2009). Patient demographics, presenting symptoms, preoperative imaging, intraoperative findings, pathology, hospital course, outcomes, level of caval involvement, renal artery embolization, liver mobilization, blood loss, transfusion requirements and follow up times were recorded.
Results: Median patient BMI (n=8) was 25.7 (18.3-31.9). Eight… More >

Bob Djavan

Canadian Journal of Urology, Vol.18, No.1, pp. 5536-5536, 2011

Abstract This article has no abstract. More >

Jacobo Arce, Josep M. Gaya, Jorge Huguet, Oscar Rodriguez, Joan Palou, Humberto Villavicencio

Canadian Journal of Urology, Vol.18, No.1, pp. 5529-5536, 2011

Abstract Objectives: To determine which patients may benefit from prostate-sparing surgery and which factors are predictive of invasive prostatic involvement.
Materials and methods: A total of 717 men underwent radical cystoprostatectomy (RC) for bladder transitional cell carcinoma (TCC) between 1978 and 2002. Analysis of prostatic urethral involvement by transitional cell carcinoma (pTCC) and of invasive prostatic involvement by TCC was performed according to recurrence, presence of carcinoma in situ (CIS) and multifocality, previous intravesical chemotherapy, grade, stage and location of bladder tumor, presence of CIS in precystectomy transurethral resection (TUR) and indication for RC.
Results: pTCC was present in… More >

Francesca Vita¹, Salvatore Siracusano², Rita Abbate¹, Stefano Ciciliato², Violetta Borelli¹, Maria Rosa Soranzo¹, Giuliano Zabucchi¹

Canadian Journal of Urology, Vol.18, No.1, pp. 5517-5523, 2011

Abstract Introduction: Bacillus Calmette-Guérin (BCG) is used to treat high risk superficial bladder cancer, but its anti-tumor effect remains incompletely defined. Recently a role for polymophonuclear (PMN) neutrophils has been suggested. To investigate the role of granulocytes, we monitored the activation state of these cells in the urine of BCG-treated patients.
Materials and methods: Ten patients with stage T1, grade 3 (T1G3) transitional cell carcinoma received an 8 week course of BCG after undergoing transurethral resection of the bladder. Cytological and enzymatic analyses of urine samples collected before and 2 hours after the physiological expulsion of BCG were… More >

Arnaldo Mendez, Mohamad Sawan

Canadian Journal of Urology, Vol.18, No.1, pp. 5504-5516, 2011

Abstract Chronic monitoring of bladder volume can improve the clinical diagnosis and the choice of therapeutic approach for patients suffering from urinary dysfunction. It can also be employed to notify patients or healthcare personnel when the bladder should be emptied. An early warning can be triggered either when functional bladder capacity is reached or when an abnormally high postvoiding residual volume remains in the bladder after an unfinished voiding. Currently, neuroprosthetic implants are used in the treatment of refractory patients with overactive bladder, with urgency-frequency or with voiding complications. These implants can further enhance their performance, More >

Leonard G. Gomella

Canadian Journal of Urology, Vol.18, No.1, pp. 5500-5500, 2011

Abstract This article has no abstract. More >

Jay Heintz, Barbara Kahn, Andrew Kramer

Canadian Journal of Urology, Vol.18, No.2, pp. 5660-5662, 2011

Abstract Introduction: To report an unusual presentation of metastatic prostate cancer to the orbit in an immunosuppressed patient, who received a novel palliative treatment regimen.
Materials and methods: A 56 year old HIV+ man presented with proptosis and unilateral blindness. The diagnosis, work up, and treatment are outlined.
Results: Metastatic prostate cancer to the orbit is diagnosed, and the treatment with IMRT and hormone ablation is explored.
Conclusion: We outline the literature and current thinking surrounding prostate cancer metastases to the orbit. HIV+ patients currently enjoy longer life expectancies, with the caveat that their immunosuppressed status may lead to more More >